Moderna share bends: Moderna continues to write deep red numbers – restructuring should bring turn

The Biontech competitor Moderna is still deep in the red numbers. In the second quarter of 2025, the company lost $ 2.13 per share, after a minus of $ 3.33 per share in the comparison period of the previous year. Analysts had expected persistent losses in advance, their EPS estimates had amounted to an average of -2.963 US dollars per share.

Moderna’s turnover was $ 142 million in the reporting period. That was significantly less than in the comparison quarter of the previous year when the group implemented $ 241 million. In their estimates, the experts had expected a drop in sales to $ 113 million.

Moderna terminates restructuring and Job cuts to

Moderna is also faced with a profound conversion: The US Biotech Group announced a drastic step towards realignment on Thursday. As CEO Stéphane Bancel explained in a company announcement, the company will reduce around ten percent of its workforce worldwide. By the end of the year, the number of employees is to be reduced to less than 5,000. The decision was not easy, said Bancel, but necessary to adapt the cost structure to business realities and at the same time ensure long -term investments in research.

Moderna had already set itself the goal of reducing annual operating costs by 2027 at the beginning of the year. According to Bancel, progress has been achieved in recent months by reducing research expenditure, new negotiations with suppliers and lower manufacturing costs. The now announced job cuts was the last remedy after all other austerity measures had previously been exhausted.

Moderna looks forward to the front

Despite the tense situation, the company is confident. With currently three approved products and the prospect of up to eight other approvals in the next three years, Bancel sees the future of the company positively. In the future, the focus will be even more on oncology, rare diseases and latent viruses. “We sharpen our strategic orientation, remain ambitious and continue to invest in scientific progress,” Bancel emphasized in his letter to the employees.

This is how the Moderna share develops

The Moderna share temporarily loses 8.81 percent to $ 26.96 on Friday. On Thursday, the paper was ultimately overrun by 8.06 percent to $ 29.56 after the announcement of the restructuring measures in the US trade.

Editor finance.net

Selected leverage products on Moderna

With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Moderna

The lever must be between 2 and 20

Advertising